Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Pharma in Dogged Fight against Expansion of CEA Price Tweaks, Flags “Camel’s Nose”
November 29, 2023
- Japan Ambassador Meets Astellas Employee Detained in China
November 29, 2023
- Japan Approves Meiji’s COVID Vaccine, Daiichi Sankyo’s XBB-Tailored Jab
November 28, 2023
- Syphilis Cases in Japan Mark Record High for 3rd Consecutive Year
November 28, 2023
- LDP League Leader Vows to Push Self-Medication to Sustain Healthcare System
November 28, 2023
- LDP League on Medical Patches Cautions against Hasty Debate on LLP Copay
November 28, 2023
- Medipharma Altered Data in at Least 7 Clinical Trials: MHLW
November 28, 2023
- Meiji’s mRNA Vaccine, Pfizer’s RSV Vaccine Now in Line for Approval
November 28, 2023
- Chuikyo Supports Adding More Dosage Forms to “Minimum Price” Category, Urges Improvements in Distribution Practices
November 27, 2023
- HCPs, Payers Spat over Extension of Add-On Fee Premiums Related to Drug Supply Issues
November 27, 2023
- As Leqembi Listing Approaches, Chuikyo OKs Coverage for PET Device and Diagnostics
November 27, 2023
- Ultragenyx’s Evinacumab, Alexion’s Danicopan Up for Japan Panel Review on Dec. 8
November 27, 2023
- Pool Fever Reaches Alert Level in Japan for 1st Time in Decade: NIID
November 27, 2023
- Japan Deeping Debate on LLP Copay Review; Focus Is on Exclusion Criteria, Payment Levels, G1/G2 Rule Change
November 27, 2023
- Japan Approves Label Expansions for Opdivo, Adcetris, and More
November 27, 2023
- Japan Grants Orphan Tags to MSD’s MK-3475A, 3 More Drugs
November 27, 2023
- COVID Vaccines to Join NIP for Ages 65-Plus from April, with Copay Required
November 24, 2023
- No Objections to Better Premiums, Easing of Re-Pricing as Incentives for Pediatric Drug Development: Chuikyo
November 24, 2023
- Chuikyo Reps Split on Nixing PMP Company Criteria; Many Back Review of Reduction Caps under Re-Pricing
November 24, 2023
- MHLW Proposes Posting Reported Drug Supply Concerns on Its Website
November 22, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…